News and Announcements
Proteomics Targets Gastro-Causing Parasite
- Published October 20, 2016 11:16AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
20th October 2016, ASX Announcement
Perth life sciences company Proteomics International Laboratories Ltd (PILL, ASX: PIQ) has successfully applied its biomarker discovery platform Promarker to the parasite Giardia.
- PILL maps samples from the gastro-causing parasite Giardia.
- Giardiasis is one of the most common waterborne diseases worldwide.
- Secures commercial funding and Federal Entrepreneurs’ Programme grant to help commercialise the test.
- PILL to receive a royalty stream from net sales for any diagnostic test.
PILL used the company’s proprietary technology to map samples of the gastro-causing parasite, searching for protein ‘fingerprints’ that can distinguish between different strains.
The proof-of-concept study was conducted in collaboration with Murdoch University and on a feefor-service basis with a leading US veterinary company. This collaboration will now be extended with the aim to develop a commercial diagnostic test for Giardia, and a licence agreement is in place to ensure PILL receives a royalty stream from sales of any test.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
